Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SHR 1501

Next Previous
Drug Profile

SHR 1501

Alternative Names: SHR-1501

Latest Information Update: 24 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action CD8 positive T lymphocyte stimulants; Interleukin 15 stimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Bladder cancer
  • No development reported Cancer

Most Recent Events

  • 07 Jul 2025 Jiangsu Hengrui Medicine plans a phase I/II trial for Solid tumours (Late-stage disease, Metastatic disease and Combination therapy) in China in July 2025 (SC) (NCT07073534)
  • 28 Jun 2025 No recent reports of development identified for phase-I development in Cancer(Combination therapy, Late-stage disease, Metastatic disease) in China (SC)
  • 30 May 2025 Efficacy and adverse events data from a phase I trial in Bladder cancer presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top